PAPantep Angchaisuksiri

Pantep Angchaisuksiri

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pantep Angchaisuksiri has a total of 136 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The MAPTO survey: worldwide approaches on unmasking factor VIII inhibitors in children with emicizumab treatment: communication from the ISTH SSC Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders

    by Lilianne Esmée van Stam, Bridget Jane Daisy Horstman, Pantep Angchaisuksiri, Manuel Carcao, Gili Kenet, Christoph Königs, Johnny Mahlangu, Maria Elisa Mancuso, Suely Meireles Rezende, Robert Francis Sidonio, et al.


  • Open Access

    A commitment to global collaboration, welcoming international participation and advancing science for the benefit of patients

    by Pantep Angchaisuksiri, Wolfram Ruf, Jeffrey Weitz, Sam Schulman, Guy A. Young

    On behalf of the International Society on Thrombosis and Haemostasis (ISTH) Council and Annual Congress Planning Committee (ACPC) As we prepare for the International Society on Thrombosis and Haemostasis (ISTH) 2025 Congress in Washington, D.C., we are reminded of the strength and significance of our global community. The ISTH remains firmly dedicated to advancing science, supporting research and fostering innovation across borders. Now more than ever, we encourage the global ISTH community to come together—not just as individuals or institutions, but as a collective committed to building connections, exchanging knowledge, advancing science and improving patient care.

  • Top Cited Papers
    Open Access

    International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital hemophilia A and B based on the Grading of Recommendations Assessment, Development, and Evaluation methodology

    by Suely M. Rezende, Ignacio Neumann, Pantep Angchaisuksiri, Omolade Awodu, Ana Boban, Adam Cuker, Julie A. Curtin, Karin Fijnvandraat, Samantha C. Gouw, Roberta Gualtierotti, et al.


  • Open Access

    Haemophilia care in Asia: Learning from clinical practice in some Asian countries

    by Pantep Angchaisuksiri, Marilou Amurao‐Abiera, Sheng‐Chien Chou, Pol Chewcharat, Novie Amelia Chozie, Roy Gomez, Tien Sim Leng, Pei‐Chin Lin, Nguyen Thi Mai, Zulaiha Muda, et al.

    Background: The healthcare systems in Asia vary greatly due to the socio‐economic and cultural diversities which impact haemophilia management.Methods: An advisory board meeting was conducted with experts in haemophilia care from Asia to understand the heterogeneity in clinical practices and care provision in the region.Findings: The overall prevalence of haemophilia in Asia ranges between 3 and 8.58/100,000 patients. Haemophilia A was more prevalent as compared to haemophilia B with a ratio of around 5:1. There is under‐diagnosis in the region due to lack of diagnosis, registries and/or lack of appropriate facilities in suburban areas. Most patients are referred to the haematologists by their families or primary care physicians, while some are identified during bleeding episodes. Genetic testing faces obstacles like resource constraints, services available at limited centres and unwillingness of patients to participate. Prophylaxis is offered for people with haemophilia (PWH) with a severe bleeding phenotype. Recombinant factors are approved in most countries across the region and are the preferred therapy. The challenges highlighted for not receiving a high standard of care include patients’ reluctance to use an intravenous treatment, poor patient compliance due to frequency of infusions, budget constraints and lack of funding, insurance, availability and accessibility of factor concentrates. Prevalence of neutralizing antibodies ranged from 5% to 20% in the region. Use of immune tolerance induction and bypassing agents to treat inhibitors depends on their cost and availability.Conclusion: Haemophilia care in Asia has evolved to a great extent. However, some challenges remain for which a strategic approach along with multi‐stakeholder involvement are needed.


  • Open Access

    Incidence of anti-platelet factor4/polyanionic antibodies, thrombocytopenia, and thrombosis after COVID-19 vaccination with ChAdOx1 nCoV-19 in Thais

    by Kochawan Boonyawat, Tichayapa Phojanasenee, Phichchapha Noikongdee, Pornnapa Police, Pichika Chantrathammachart, Pimjai Niparuck, Teeraya Puavilai, Angsana Phuphuakrat, Pantep Angchaisuksiri

    Background: The prevalence of anti-platelet factor 4 (PF4)/polyanionic antibodies occurring after vaccination with ChAdOx1 nCoV-19 is low. Most of these antibodies are not associated with vaccine-induced thrombotic thrombocytopenia. It remains unknown whether these antibodies are preexisting or occur as a result of vaccination. In this study, we demonstrated the incidence of anti-PF4/polyanionic antibodies, thrombocytopenia, and thrombosis after vaccination with ChAdOx1 nCoV-19 in a large cohort of Thais. Methods: We conducted a prospective study in a cohort of health care workers and members of the general population who received COVID-19 vaccination with ChAdOx1 nCoV-19. Blood collection for complete blood count, D-dimer, and anti-PF4/polyanionic antibodies was performed before vaccination (day 0), day 10, and day 28 after vaccination. Anti-PF4/polyanionic antibodies were detected using enzyme-link immunosorbent assay (ELISA). Functional assay was performed for all positive ELISA tests. Results: A total of 720 participants were included in the study. 214 participants received both the first and second doses, 91 participants received only the first, 51 received only the second, and 364 received the third booster dose of ChAdOx1 nCoV-19. Median age was 42 years (IQR, 34–53). 67% of participants were female. Three participants developed seroconversion, yielding an incidence of vaccination-induced anti-PF4/polyanionic antibodies of 0.42% (95% confidence interval 0.08, 1.23). Fourteen (1.9%) participants had preexisting anti-PF4/polyanionic antibodies before the vaccination but their optical density of anti-PF4/polyanionic antibodies did not significantly increase over time. None of the anti-PF4/polyanionic positive sera induced platelet aggregation. Abnormal D-dimer levels following vaccination were not different among the positive and negative anti-PF4/polyanionic groups (11.8% vs. 13.2%, p = 0.86). Thrombocytopenia occurred in one person with negative anti-PF4/polyanionic antibodies. No clinical thrombosis or bleeding occurred. Conclusion: We found a low incidence of seroconversion of anti-PF4/polyanionic antibodies after vaccination with ChAdOx1 nCoV-19 in Thais. Most of the anti-PF4/polyanionic antibodies were preexisting and did not significantly increase after vaccination with ChAdOx1 nCoV-19. Following vaccination, some participants with anti-PF4/polyanionic antibodies had elevated D-dimer levels, while only one developed thrombocytopenia and no thrombotic events were observed.


  • Open Access

    Incidence of anti-platelet factor4/polyanionic antibodies, thrombocytopenia, and thrombosis after COVID-19 vaccination with ChAdOx1 nCoV-19 in Thais

    by Kochawan Boonyawat, Tichayapa Phojanasenee Mmt, Phichchapha Noikongdee, Pornnapa Police Mmt, Pichika Chantrathammachart, Pimjai Niparuck, Teeraya Puavilai, Angsana Phuphuakrat, Pantep Angchaisuksiri

    Background The prevalence of anti-platelet factor 4 (PF4)/polyanionic antibodies occurring after vaccination with ChAdOx1 nCoV-19 is low. Most of these antibodies are not associated with vaccine-induced thrombotic thrombocytopenia. It remains unknown whether these antibodies are preexisting or occur as a result of vaccination. In this study, we demonstrated the incidence of anti-PF4/polyanionic antibodies, thrombocytopenia, and thrombosis after vaccination with ChAdOx1 nCoV-19 in a large cohort of Thais. Methods We conducted a prospective study in a cohort of health care workers and members of the general population who received COVID-19 vaccination with ChAdOx1 nCoV-19. Blood collection for complete blood count, D-dimer, and anti-PF4/polyanionic antibodies was performed before vaccination (day 0), day 10, and day 28 after vaccination. Anti-PF4/polyanionic antibodies were detected using enzyme-link immunosorbent assay (ELISA). Functional assay was performed for all positive ELISA tests. Results A total of 720 participants were included in the study. 214 participants received both the first and second doses, 91 participants received only the first, 51 received only the second, and 364 received the third booster dose of ChAdOx1 nCoV-19. Median age was 42 years (IQR, 34–53). 67% of participants were female. Three participants developed seroconversion, yielding an incidence of vaccination-induced anti-PF4/polyanionic antibodies of 0.42% (95% confidence interval 0.08, 1.23). Fourteen (1.9%) participants had preexisting anti-PF4/polyanionic antibodies before the vaccination but their optical density of anti-PF4/polyanionic antibodies did not significantly increase over time. None of the anti-PF4/polyanionic positive sera induced platelet aggregation. Abnormal D-dimer levels following vaccination were not different among the positive and negative anti-PF4/polyanionic groups (11.8% vs 13.2%, p = 0.86). Thrombocytopenia occurred in one person with negative anti-PF4/polyanionic antibodies. No clinical thrombosis or bleeding occurred. Conclusion We found a low incidence of seroconversion of anti-PF4/polyanionic antibodies after vaccination with ChAdOx1 nCoV-19 in Thais. Most of the anti-PF4/polyanionic antibodies were preexisting and did not significantly increase after vaccination with ChAdOx1 nCoV-19. Following vaccination, some participants with anti-PF4/polyanionic antibodies had elevated D-dimer levels, while only one developed thrombocytopenia and no thrombotic events were observed.

  • Open Access

    Practices and challenges for hemophilia management under resource constraints in Thailand

    by Chatphatai Moonla, Darintr Sosothikul, Bunchoo Pongtanakul, Bundarika Suwanawiboon, Chanchai Traivaree, Rungrote Natesirinilkul, Nongnuch Sirachainan, Pantep Angchaisuksiri

    Hemophilia is an inherited bleeding disorder caused by deficiency of a specific coagulation factor. Factor VIII deficiency is responsible for hemophilia A while factor IX deficiency is responsible for hemophilia B. As per the 2020 annual global survey by the World Federation of Hemophilia, only 1828 Thai hemophiliacs have been registered to the national healthcare system. The reason for the low number is the underdiagnosis which is a major concern in the real-world practice among Asian countries. In Thailand, most hemophiliacs are diagnosed by general practitioners, pediatricians or internists at rural hospitals and are referred to hemophilia specialists at the Hemophilia Treatment Centers (HTCs). Despite the challenges pertaining to infrastructure and cost of treatment, Thailand has progressed substantially in providing the required hemophilia care, as evidenced by an evolution in acquiring and sharing knowledge as well as collaborative efforts among multiple stakeholders over the past three decades. In this letter-to-the-editor, the authors have summarized the practices for and challenges faced with hemophilia management in Thailand.


  • Open Access

    Thrombosis and anticoagulation: clinical issues of special importance to hematologists who practice in Asia

    by Kochawan Boonyawat, Pantep Angchaisuksiri

    There are clinical issues of special importance and practice variation in the management of venous thromboembolism (VTE) and in the use of anti co ag u lants among hema tol o gists who prac tice in Asia. In Asian -inherited thrombophilia, coag u la tion is dis turbed due to loss -of -func tion muta tions of pro tein S and pro tein C caus ing pro tein S and pro tein C deficiencies, whereas the gain -of -func tion fac tor V Leiden and pro throm bin G20210A muta tions are almost absent. Thrombophilia screen ing is not recommended in patients with VTE patients who have major pro vok ing fac tors. How-ever, it can be con sid ered in unpro voked young patients with VTE who have a strong fam ily his tory of VTE. Cancer is the most impor tant acquired risk fac tor for VTE in Asians. Limited can cer screen ing at the ini tial pre sen ta tion of unpro voked VTE is appro pri ate, espe cially in the elderly. Direct oral anti co ag u lants have been shown to have sim i lar efficacy and reduce risk of major bleeding, including intracranial hemorrhage and bleeding requiring hospitalization, compared with warfarin. Most clinical trials evaluating therapies for treatment and prevention of VTE have included small num bers of Asian patients. Despite this lack of evi dence, direct oral anti co ag u lants have been increas ingly used in Asia for can cer -asso ci ated throm bo sis. Individualized assess ment of throm botic and bleed ing risks should be used for all hos pi tal ized Asian patients when decid ing on phar ma co logic thromboprophylaxis. More research is needed to under stand the fac tors that con trib ute to risks of VTE and anti co ag u lant - asso ci ated bleed ing in Asian patients as these may differ from Western populations.


  • Open Access

    Long-Term Durable FVIII Expression with Improvements in Bleeding Rates Following AAV-Mediated FVIII Gene Transfer for Hemophilia A: Multiyear Follow-up on the Phase I/II Trial of SPK-8011

    by Stacy E. Croteau, M. Elaine Eyster, Huyen Tran, Margaret V. Ragni, Benjamin J. Samelson-Jones, Lindsey George, Spencer Sullivan, John E.J. Rasko, Jill Moormeier, Pantep Angchaisuksiri, et al.